These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 1450288)

  • 21. The influence of clozapine and typical neuroleptics on information processing of the central nervous system under clinical conditions in schizophrenic disorders: implications for fitness to drive.
    Grabe HJ; Wolf T; Grätz S; Laux G
    Neuropsychobiology; 1999 Nov; 40(4):196-201. PubMed ID: 10559702
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Value of neuroleptic therapy in the self assessment of schizophrenic patients].
    Heim M
    Psychiatr Neurol Med Psychol (Leipz); 1987 Aug; 39(8):487-91. PubMed ID: 3685210
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pupillary constriction during haloperidol treatment as a predictor of relapse following drug withdrawal in schizophrenic patients.
    Steinhauer SR; van Kammen DP; Colbert K; Peters JL; Zubin J
    Psychiatry Res; 1992 Sep; 43(3):287-98. PubMed ID: 1438625
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The relationship of clozapine and haloperidol treatment response to prefrontal, hippocampal, and caudate brain volumes.
    Arango C; Breier A; McMahon R; Carpenter WT; Buchanan RW
    Am J Psychiatry; 2003 Aug; 160(8):1421-7. PubMed ID: 12900303
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial.
    Ritsner MS; Gibel A; Ratner Y; Tsinovoy G; Strous RD
    J Clin Psychopharmacol; 2006 Oct; 26(5):495-9. PubMed ID: 16974191
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Psychometric studies of performance deficits in acute schizophrenic patients with special reference to gender].
    Classen W; Laux G
    Schweiz Arch Neurol Psychiatr (1985); 1991; 142(1):31-40. PubMed ID: 1709296
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Do neuroleptics impair learning in schizophrenic patients?
    Cutmore TR; Beninger RJ
    Schizophr Res; 1990; 3(3):173-86. PubMed ID: 1980612
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma clozapine levels and clinical benefit.
    Greenberg WM
    J Clin Psychiatry; 1995 Nov; 56(11):535-6. PubMed ID: 7592511
    [No Abstract]   [Full Text] [Related]  

  • 29. Auditory event-related potentials and electrodermal activity in medicated and unmedicated schizophrenics.
    Roth WT; Goodale J; Pfefferbaum A
    Biol Psychiatry; 1991 Mar; 29(6):585-99. PubMed ID: 1675890
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia: a 12-month, randomized, naturalistic trial.
    Cipriani A; Accordini S; Nosè M; Purgato M; Girlanda F; Tansella M; Barbui C
    J Clin Psychopharmacol; 2013 Aug; 33(4):533-7. PubMed ID: 23775051
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Social cognition and visual perception in schizophrenia inpatients treated with first-and second-generation antipsychotic drugs.
    Kucharska-Pietura K; Mortimer A; Tylec A; Czernikiewicz A
    Clin Schizophr Relat Psychoses; 2012 Apr; 6(1):14-20. PubMed ID: 22453865
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Driving simulator performance and psychomotor functions of schizophrenic patients treated with antipsychotics.
    Brunnauer A; Laux G; Zwick S
    Eur Arch Psychiatry Clin Neurosci; 2009 Dec; 259(8):483-9. PubMed ID: 19593580
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Somatosensory-evoked potential changes during haloperidol treatment of chronic schizophrenics.
    Saletu B; Saletu M; Itil T; Marasa J
    Biol Psychiatry; 1971; 3(4):299-307. PubMed ID: 5163816
    [No Abstract]   [Full Text] [Related]  

  • 34. Vigilance deficits in schizophrenics and affectively disturbed patients.
    Rund BR; Orbeck AL; Landrø NI
    Acta Psychiatr Scand; 1992 Sep; 86(3):207-12. PubMed ID: 1414414
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients.
    Krakowski MI; Czobor P; Nolan KA
    J Clin Psychopharmacol; 2008 Oct; 28(5):485-93. PubMed ID: 18794642
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison.
    Kane JM; Marder SR; Schooler NR; Wirshing WC; Umbricht D; Baker RW; Wirshing DA; Safferman A; Ganguli R; McMeniman M; Borenstein M
    Arch Gen Psychiatry; 2001 Oct; 58(10):965-72. PubMed ID: 11576036
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome.
    Buchanan RW; Breier A; Kirkpatrick B; Ball P; Carpenter WT
    Am J Psychiatry; 1998 Jun; 155(6):751-60. PubMed ID: 9619146
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Coping style and cognitive dysfunction in schizophrenic patients.
    van den Bosch RJ; van Asma MJ; Rombouts R; Louwerens JW
    Br J Psychiatry Suppl; 1992 Oct; (18):123-8. PubMed ID: 1389035
    [No Abstract]   [Full Text] [Related]  

  • 39. Procedural learning improvements after six weeks of clozapine treatment.
    Purdon SE; Woodward ND; Mintz A; LaBelle A
    Schizophr Res; 2002 Jan; 53(1-2):165-6. PubMed ID: 11728847
    [No Abstract]   [Full Text] [Related]  

  • 40. Chronic haloperidol treatment does not affect structure of attention in schizophrenia.
    Allen DN; Gilbertson MW; van Kammen DP; Kelley ME; Gurklis JA; Barry EJ
    Schizophr Res; 1997 May; 25(1):53-61. PubMed ID: 9176927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.